IOLMaster® 500

Article

With automatic and non-contact measurement of the patient's eye, the new IOLMaster 500 offers the fastest and easiest way of calculating the right IOL for each patient.

Today, selecting the right IOL to meet individual patient expectations is more crucial than ever. With automatic and non-contact measurement of the patient's eye, the new IOLMaster 500 offers the fastest and easiest way of calculating the right IOL for each patient. As a complete workstation for user-friendly biometry and totally reliable IOL selection, the IOLMaster 500 represents the latest generation of optical biometry that is specially designed to meet the needs of a modern cataract practice. The guiding principles behind its development: precision, simplicity, outcomes.

Precision
Dependable data for clinical confidence

With the IOLMaster 500, the high level of clinical confidence is easier to achieve than ever: In the new dual measurement mode, multiple axial length and keratometry readings are captured largely automatically, with a simple push of a button.

Simplicity
Customer-centric innovation in biometry

The IOLMaster 500 re-defines simplicity. Its redesigned graphical user interface yields more data with fewer clicks. The optional Sonolink ultrasound connection provides an optimal workflow even for those few cases where an optical axial length reading is not possible.

Outcomes
Clinical results that make a difference

The long clinical experience with the IOLMaster is reflected by the Users’ Group for Interference Biometry (ULIB) website. For virtually all common IOL types, the ULIB database contains lens constants optimized specifically for the IOLMaster. And the IOLMaster 500 allows these constants to be further refined and personalized.

For more information on the IOLMaster 500 visit www.meditec.zeiss.com/iolmaster or www.iolmaster-online.zeiss.com

Carl Zeiss Meditec AG
Jena / Germany
Phone: +49 36 41 22 03 33
info@meditec.zeiss.comwww.meditec.zeiss.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.